Your session is about to expire
← Back to Search
Abatacept for Chronic Cytopenia in CTLA4 Haploinsufficiency
Study Summary
This trial is testing the safety and efficacy of abatacept as a treatment for CTLA4 deficiency, which can cause problems with the immune system. Eligible participants will receive either the study drug or a placebo for six months, and will be monitored for improvement.
- CTLA4 Haploinsufficiency
- Chronic Cytopenia
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 16 Patients • NCT02078882Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had an allergic reaction to abatacept in the past.You have had any type of cancer (except for a type of skin cancer called basal cell carcinoma) within the past 5 years, even if it has been treated or has not spread.
- Group 1: placebo
- Group 2: abatacept
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is registration open for this investigation presently?
"The trial information available on clinicaltrials.gov confirms that the experiment is actively seeking participants; it was originally uploaded to the website on December 6th, 2022 and underwent its latest update by November 30th of the same year."
How many participants have registered for this medical trial to date?
"Indeed, based on the information available on clinicaltrials.gov, this medical trial is actively enrolling patients. It was posted online in December 6th 2022 and last updated at the end of November 2022. The research team has set a goal to recruit 40 participants from one centre for their study."
Are individuals aged over 30 eligible for inclusion in this clinical experiment?
"This medical trial seeks participants aged 8 or above and under 65."
What criteria must potential participants meet in order to be eligible for this research?
"This trial is searching for 40 volunteers between 8 and 65 years of age who have ctla4 haploinsufficiency. They must also not have increased their medication dose, received abatacept within the last two months or blood transfusions in the last 30 days, nor started any new medications to treat cytopenia during that time frame. Additionally, they should require active treatment with steroids, immunomodulatory agents like mycophenolate mofetil and cyclosporine , tacrolimus mercaptopurine methotrexate sirolimus and high-dose intravenous immunoglobulin"
What afflictions does abatacept frequently alleviate?
"Abatacept is a therapeutic option for those living with rheumatoid arthritis, as well as psoriatic arthirtis, polyarticular juvenile idiopathic arthritis (JIA), and the more serious variant of JIA."
What precedent has been established with regards to abatacept's application in clinical studies?
"Currently, abatacept is the subject of 34 ongoing trials, 8 of which are in their third phase. Multiple locations across Toronto offer these studies, with a total count of 771 clinics hosting research on this drug."
Share this study with friends
Copy Link
Messenger